Marie Francisco, MD
Family Medicine · Stockton, CANPI 1598721003
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$870
- Boehringer Ingelheim$455
- Pfizer$401
- Amarin Pharma, Inc.$365
- Bayer$248
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,995100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $1,038 |
| AstraZeneca | 31 | $870 |
| Boehringer Ingelheim | 18 | $455 |
| Pfizer | 20 | $401 |
| Amarin Pharma, Inc. | 19 | $365 |
| Bayer | 7 | $248 |
| Idorsia Pharmaceuticals US Inc | 14 | $222 |
| Sanofi-aventis U.S. LLC | 12 | $189 |
| Lilly USA, LLC | 11 | $176 |
| Amgen | 7 | $163 |
| GSK | 9 | $144 |
| AbbVie | 6 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $91 |
| Novartis | 4 | $76 |
| Exact Sciences | 3 | $64 |
| Lundbeck LLC | 2 | $62 |
| Ironwood Pharmaceuticals, Inc | 2 | $40 |
| Corcept Therapeutics | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Mannkind Corporation | 2 | $24 |
| Intra-sana Laboratories | 1 | $23 |
| Qiagen, LLC | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Forte Bio-pharma LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Silk Road Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,995 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 167 | $209,106 |
| OzempicSemaglutide | 60 | $63,575 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $52,513 |
| RybelsusSemaglutide | 23 | $44,636 |
| FarxigaDapagliflozin Propanediol | 35 | $42,574 |
| VascepaIcosapent Ethyl | 62 | $39,861 |
| LinzessLinaclotide | 34 | $37,356 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $30,097 |
| JanuviaSitagliptin Phosphate | 17 | $18,769 |
| EliquisApixaban | 32 | $17,971 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $16,342 |
| TradjentaLinagliptin | 18 | $16,035 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 282 | $9,941 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,920 |
| Atorvastatin Calcium | 1,155 | $9,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $455 | $225,141185 claims |
| Novo NordiskOzempic, Rybelsus | $1,038 | $108,21283 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $144 | $60,93168 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $870 | $52,49446 claims |
| AbbVieLinzess | $103 | $37,35634 claims |
| PfizerEliquis | $401 | $17,97132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Stockton
- Atul VermaStockton$195K
- Daniel CooperStockton$79K
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.